Login
Companies $CGON
$84.48 -$0.30 (0.35%) After hours
CG Oncology, Inc. logo

CG Oncology, Inc.

cgoncology.com

What Do They Do?

Develops cretostimogene, an investigational therapy for people with high- and intermediate-risk bladder cancer.

How Do They Make Money?

Commercial and development revenue (80% of revenue) comes from manufacturing products supplied to customers. License and collaboration agreements generate upfront payments, development milestones when achieved, and royalties tied to licensed-product sales.

revenue
SegmentShareRevenue
Commercial and Development Revenue
Sold outright

80%
License and Collaboration Revenue
Licensed

20%

Who Are Their Customers?

Kissei receives a territorial license and purchases its clinical and commercial product supply directly; under supply arrangements, customers typically provide the active ingredient or other proprietary materials used in manufacturing.

Do Revenues Turn Into Profits?

No. It lost $161M in FY2025.

Operating income, FY2025
−4722% of revenue
▼ −66% (Loss) vs FY2024 (−$114.7M, −10067%)
Net income, FY2025
−3985% of revenue
▼ −83% (Loss) vs FY2024 (−$88M, −7729%)
Free cash flow, FY2025
−3279% of revenue
▼ −68% (Loss) vs FY2024 (−$78.9M, −6931%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −4%
vs $1.7M in Q3 FY2025
Commercial and development revenue share of revenue vs 90.5% in Q3 FY2025
  • Apr 13, 2026 Appointed Jim DeTore as chief financial officer
Revenue over time
Commercial and Development Revenue License and Collaboration Revenue
$5M$2.5M$0

Who Do They Compete With?

Competes with Bristol Meyers Squibb, enGene, Gilead Sciences, Hoffman-La Roche, ImmunityBio, Johnson & Johnson, Merck, Protara Therapeutics, Pfizer, Relmada Therapeutics, and UroGen Pharma

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support